Corrigendum: Sanqi Oral Solution Mitigates Proteinuria in Rat Passive Heymann Nephritis and Blocks Podocyte Apoptosis via Nrf2/HO-1 Pathway

Xiaowan Wang; Jinchu Liu; Ruimin Tian; Bidan Zheng; Chuang Li; Lihua Huang; Zhisheng Lu; Jing Zhang; Wei Mao; Bo Liu; Kun Bao; Peng Xu

doi:10.3389/fphar.2022.905693

Corrigendum: Sanqi Oral Solution Mitigates Proteinuria in Rat Passive Heymann Nephritis and Blocks Podocyte Apoptosis via Nrf2/HO-1 Pathway

Front Pharmacol. 2022 Apr 27:13:905693. doi: 10.3389/fphar.2022.905693. eCollection 2022.

Authors

Xiaowan Wang^{1

2

3

4}, Jinchu Liu^{1

2}, Ruimin Tian^{1

2

3

4}, Bidan Zheng¹, Chuang Li^{1

2

3

4}, Lihua Huang^{1

2

3

4}, Zhisheng Lu^{1

2}, Jing Zhang^{1

4}, Wei Mao^{1

2

3

4}, Bo Liu^{1

4

5}, Kun Bao^{1

2

3

4}, Peng Xu^{1

2

3

4}

Affiliations

¹ State Key Laboratory of Dampness Syndrome of Chinese Medicine, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, China.
² Department of Nephrology, Guangdong Provincial Hospital of Chinese Medicine, Guangzhou, China.
³ Guangdong Provincial Key Laboratory of Chinese Medicine for Prevention and Treatment of Refractory Chronic Diseases, Guangzhou, China.
⁴ Guangdong Provincial Academy of Chinese Medical Sciences, Guangzhou, China.
⁵ Guangzhou Key Laboratory of Chirality Research on Active Components of Traditional Chinese Medicine, Guangzhou, China.

Abstract

[This corrects the article DOI: 10.3389/fphar.2021.727874.].

Keywords: Nrf2/ HO-1 signaling pathway; Sanqi oral solution; passive Heymann nephritis; podocyte apoptosis; proteinuria.

Publication types

Published Erratum